Use my Search Websuite to scan PubMed, PMCentral, Journal Hosts and Journal Archives, FullText. Kick-your-searchterm to multiple Engines kick-your-query now !>

A dictionary by aggregated review articles of nephrology, medicine and the life sciences Your one-stop-run pathway from word to the immediate pdf of peer-reviewed on-topic knowledge.

10.1016/j.intimp.2021.107512 http://scihub22266oqcxt.onion/10.1016/j.intimp.2021.107512 33735714!7923863!33735714     free     free     free Deprecated: Implicit conversion from float 233.6 to int loses precision in C:\Inetpub\vhosts\kidney.de\httpdocs\pget.php on line 534 Deprecated: Implicit conversion from float 233.6 to int loses precision in C:\Inetpub\vhosts\kidney.de\httpdocs\pget.php on line 534 Deprecated: Implicit conversion from float 233.6 to int loses precision in C:\Inetpub\vhosts\kidney.de\httpdocs\pget.php on line 534 Deprecated: Implicit conversion from float 233.6 to int loses precision in C:\Inetpub\vhosts\kidney.de\httpdocs\pget.php on line 534 Deprecated: Implicit conversion from float 233.6 to int loses precision in C:\Inetpub\vhosts\kidney.de\httpdocs\pget.php on line 534 Deprecated: Implicit conversion from float 233.6 to int loses precision in C:\Inetpub\vhosts\kidney.de\httpdocs\pget.php on line 534       Int+Immunopharmacol 2021 ; 95 (ä): 107512 Nephropedia Template TP {{tp|p=33735714|t=2021. Serum Amyloid A Protein as a useful biomarker to predict COVID-19 patients severity and prognosis |pdf=|usr=}}{{33735714}} gab.com Text Serum Amyloid A Protein as a useful biomarker to predict COVID-19 patients severity and prognosis JO: Int Immunopharmacol http://www.kidney.de/pget.php?&tw=1&pmid=33735714 #FOAvip Coronavirus Disease 2019 (COVID-19) can present with different grades of severity from mild to critical. Evaluation of biomarkers predicting severity is crucial to identify patients at high risk of disease progression and poor prognosis. Serum Amyloid A (SAA) is an acute-phase protein mainly produced by the liver in response to pro-inflammatory cytokines. In this study, we investigated SAA levels at admission (T1) and after 15 days (T2) of hospitalization in two groups of patients: survivors and non-survivors. At T1, the non-survivors showed higher SAA level than survivors (74 mg/dL vs 48.75 mg/dL). At T2, the survivor group value decreased to 6.55 mg/dL, the non-survivor group still showed high levels (51.1 mg/dL). The SAA level in control group was 0.35 mg/dL. Furthermore, a cut-off value of 63 mg/dL able to discriminate survivors from non-survivors was established by ROC curve analysis at T1. At T2, the cut-off decreased to 30.9 mg/dL. A similar decreasing trend was observed for D-Dimer, hsCRP, IL-6 and procalcitonin levels. The results of this retrospective study suggest that SAA is a good marker of COVID-19 disease alone and/or in combination with other inflammatory biomarkers. Identification of reliable prognostic analytes is of great clinical relevance, as it would improve patient management besides being costs saving. Twit Text FOAVip Serum Amyloid A Protein as a useful biomarker to predict COVID-19 patients severity and prognosis ????Int Immunopharmacol http://www.kidney.de/pget.php?&tw=1&pmid=33735714 #FOAvip Twit Text # Free Paper on # # # # # LINK http://www.kidney.de/pget.php?&tw=1&pmid=33735714 #FOAvip English Wikipedia <ref>{{Cite pmid|33735714}}</ref> Serum Amyloid A Protein as a useful biomarker to predict COVID-19 patients severity and prognosis #MMPMID33735714 Pieri M; Ciotti M; Nuccetelli M; Perrone MA; Calio MT; Lia MS; Minieri M; Bernardini S Int Immunopharmacol 2021[Jun]; 95 (ä): 107512 PMID33735714show ga Coronavirus Disease 2019 (COVID-19) can present with different grades of severity from mild to critical. Evaluation of biomarkers predicting severity is crucial to identify patients at high risk of disease progression and poor prognosis. Serum Amyloid A (SAA) is an acute-phase protein mainly produced by the liver in response to pro-inflammatory cytokines. In this study, we investigated SAA levels at admission (T1) and after 15 days (T2) of hospitalization in two groups of patients: survivors and non-survivors. At T1, the non-survivors showed higher SAA level than survivors (74 mg/dL vs 48.75 mg/dL). At T2, the survivor group value decreased to 6.55 mg/dL, the non-survivor group still showed high levels (51.1 mg/dL). The SAA level in control group was 0.35 mg/dL. Furthermore, a cut-off value of 63 mg/dL able to discriminate survivors from non-survivors was established by ROC curve analysis at T1. At T2, the cut-off decreased to 30.9 mg/dL. A similar decreasing trend was observed for D-Dimer, hsCRP, IL-6 and procalcitonin levels. The results of this retrospective study suggest that SAA is a good marker of COVID-19 disease alone and/or in combination with other inflammatory biomarkers. Identification of reliable prognostic analytes is of great clinical relevance, as it would improve patient management besides being costs saving. |Adult[MESH] |Aged[MESH] |Biomarkers/blood[MESH] |C-Reactive Protein/metabolism[MESH] |COVID-19/*diagnosis[MESH] |Disease Progression[MESH] |Fibrin Fibrinogen Degradation Products/metabolism[MESH] |Humans[MESH] |Interleukin-6/blood[MESH] |Middle Aged[MESH] |Procalcitonin/blood[MESH] |Prognosis[MESH] |ROC Curve[MESH] |Retrospective Studies[MESH] |Serum Amyloid A Protein/*analysis/*metabolism[MESH] |Severity of Illness Index[MESH]Serum Amyloid A Protein as a useful biomarker to predict COVID-19 pati(epmc).pdf DeepDyve Pubget Overpricing